Teligent Inc

Teligent — IGI Laboratories — Shareholder Meeting (June 2014)

15 slides from Teligent's shareholder meeting presentation, Jun 4, 2014

  1. Slide 1: IGI Laboratories Annual Meeting of Stockholders

    IG! Laboratories, Inc. Annual Meeting of Stockholders May 29, 2014 Jason Grenfell-Gardner - President and CEO Jenniffer Collins — Chief Financial Officer NYSE:MKT (IG) Sian LABORATORIES

  2. Slide 2: Meeting agenda

    1. Call to order. 2. Announcements and introductions. 3. Declaration of quorum. 4. Voting for directors. Bs Voting for amendment to stock option plan. 6. Voting to ratify appointment of auditors. 7. Remarks by Jason Grenfell-Gardner, President and CEO 8. Results of balloting. 9. Adjournment. 10. Que

  3. Slide 3: Safe Harbor Statement

    Safe Harbor Statement Except for historical facts, the statements in this presentation, as well as oral statements or other written statements made or to be made by IGI Laboratories, Inc., are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and i

  4. Slide 4: IGI Today

    IG! Today Our mission is to be a leading player in the generic topical prescription drug market. Two platforms for growth: * Generic pharmaceuticals * Formulation and manufacturing contract services

  5. Slide 5: Our Team

    Our Team Nadya Lawrence SVP Contract Sanjay Samudre Director of Operations Jason brings significant experience in generic sales and marketing, supply chain, and management from his time at West-Ward Pharmaceuticals and Hikma Pharmaceuticals. MBA from INSEAD Jenniffer has over 20 years of experience

  6. Slide 6: IGI Transformation

    IG! Transformation 2014 is the year of IGI’s Generic Pharmaceutical Business Transformation Through Expansion and Execution Expansion of our R&D pipeline to include filing at least 10 ANDAs in 2014, and investing twice as much in R&D; and Execution of our financial objectives, to grow revenue by mor

  7. Slide 7: Generic Pharmaceuticals

    Generic Pharmaceuticals = Organic ANDA pipeline, 12 applications pending at FDA, first Intouse Rep FDA approval for IGI ANDA received in March 2014 , second tentative approval in May 2014 = Expect to submit at least 10 ANDAs in 2014 = Partnership with Medimetriks, IGI named AG distributor for Author

  8. Slide 8: Product

    Product Econazole Nitrate 1% Cream Fluocinolone Acetonide 0.01% TS AG Fluocinolone Acetonide 0.01% Cream Fluocinolone Acetonide 0.025% Cream AG Fluocinolone Acetonide 0.025% Oint AG Lidocaine 4% Topical Solution Six IGI products in ~ eleven presentations currently being marketed Compare To Spectazol

  9. Slide 9: Contract Services

    Contract Services = Product and formulation development for third parties, often resulting in a continuing manufacturing relationship Formulations = Developed more than 30 formulations in the past 2 years = Develop products for ANDAs, OTC, 510k, and cosmetics = Diverse customer base in the pharmaceu

  10. Slide 10: IGI Today

    IG! Today IGI’s facility is FDA approved to manufacture pharmaceutical products and medical devices, and passed its most recent inspection in December 2013 with zero 483 observations Our facility has the capability to produce creams, ointments, lotions, gels, solutions, and suspensions Since the fou

  11. Slide 11: The Generic Topical Market

    The Generic Topical Market = Addressable US topical market is $13.5 bn, of which generics make up 5000 $4.5 bn 5,000 = The generic space has grown rapidly, a \ CAGR of over 35% over three years } while volumes have grown <5% mar 232 error = The market has four major players and MAT 2-14 competition

  12. Slide 12: Our Pipeline

    Our Pipeline We have 12 ANDAs on file with the FDA, six under active review, with an addressable market of $330 m. ANDA Submission #6 — lidocaine hydrochloride USP 4% topical was approvedin March 2014, Submission #2 — Diclofenac Sodium 1.5% Tentatively Approved May 2014 Our Submission Timeline: 2010

  13. Slide 13: Financial Highlights

    Financial Highligh = Revenue from our contract manufacturing and formulations business has increased 20% from 2011 to 2013 = First IGI label product launched in late December 2012. In 2013, we sold four products in 8 presentations, and generated IGI label net revenue was $7.4 m in 2013 = Total reven

  14. Slide 14: Path to Profitability

    Path to Profitability USD in 0005 Ba IGI Revenue and Net Income (Loss) by Quarter 2011-2013 [=Total Revenue J=eeniet Loss/income 14

  15. Slide 15: Creating Value for our Shareholders

    ating Value for our Shareholder Accelerating R&D Efforts Raising the Bar Future Acquisitions = Expand internal R&D team = Existing and identified molecules with an addressable market of over $500 m which could be pulled forward into 2015 and 2016 approval horizon = Ability to take on products with m

IGI Laboratories — Shareholder Meeting (June 2014) on 6ix